
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR)
WebsitePrice
Market cap
Next catalystExpected 2026next-generation ACLY inhibitor (ESP-2001) · Trial initiationCompany release ↗
Cash
Chart & Events
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
Other pipelines
Approved / commercial
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved